The US FDA has approved the first fixed-dose combination of aztreonam and avibactam, in conjunction with metronidazole for treating complicated intra-abdominal infections (cIAI) in patients aged 18 years and older who have limited or no alternative treatment options. The therapy is specifically approved for CIAI cases caused by Escherichia coli, Klebsiella pneumoniae, K. oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex, and Serratia marcescens.
Clinical evidence In a clinical trial involving 422 patients, aztreonam and avibactam ± metronidazole therapy achieved a clinical cure rate comparable to meropenem ± colistin (76.4% vs. 74.0%) in CIAI patients. Dosage and administration Available as a lyophilized powder for intravenous use A combination product in a fixed 3:1 ratio Administration is based on estimated creatinine clearance Contraindications Hypersensitivity to…
